News Releases

Date	Title and Summary	View
Oct 17, 2019	Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2019 NEW BRUNSWICK, N.J. , Oct. 17, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2019 of $0.95 per share on the company's common stock. The dividend is payable on December 10, 2019 to shareholders of
Oct 15, 2019	Johnson & Johnson Reports 2019 Third-Quarter Results - Sales of $20.7 billion reflecting growth of 1.9%, operational growth of 3.2%* and adjusted operational growth of 5.2%* - EPS of $1.81 increased 25.7%; adjusted EPS of $2.12 increased 3.4%* - Company increasing Full Year Sales and EPS guidance due to strong performance NEW BRUNSWICK, N.J. , Oct.
Oct 14, 2019	U.S. FDA Approves XARELTO® (rivaroxaban) to Help Prevent Blood Clots in Acutely Ill Medical Patients
Oct 07, 2019	Janssen Submits Application to U.S. FDA Seeking Approval of STELARA® (ustekinumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Oct 03, 2019	Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Niraparib for the Treatment of Metastatic Castration-Resistant Prostate Cance
Oct 02, 2019	Janssen Submits Supplemental New Drug Application to U.S. FDA for SPRAVATO® (esketamine) CIII Nasal Spray for the Rapid Reduction of Depressive Symptoms in Adults with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent
Sep 30, 2019	U.S. FDA Approves INVOKANA® (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes (T2D) and DKD
Sep 30, 2019	Johnson & Johnson Vision Care, Inc. Introduces ACUVUE™ RevitaLens Multi-Purpose Disinfecting Solution, the Brand’s First Contact Lens Solution
Sep 27, 2019	Updated Results of the SPARTAN Study Show 25 Percent Reduction in the Risk of Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) Treated with ERLEADA® (apalutamide)
Sep 26, 2019	DePuy Synthes Expands Comprehensive Offering to Treat Degenerative Spine Disease with Launch of 3D Printed Implant Portfolio for Spine Surgery